Hepatitis C: Treatment of difficult to treat patients

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 15

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Jul 28, 2015; 7(15): 1953-1963
Published online Jul 28, 2015. doi: 10.4254/wjh.v7.i15.1953

Table 3 Food and Drug Administration approved and investigational drugs by mechanism of action

HCV NS3/4 protease inhibitors	Nucleos(t)ide HCV NS5Bpolymerase inhibitors	Non-nucleos(t)ide HCVNS5B polymerase inhibitors	HCV NS5A inhibitors
Telaprevir¹	Sofosbuvir¹	BI-207127	Daclatasvir
Boceprevir¹	Mericitabine	VX-222	Ledipasvir
Danoprevir		ABT-333	ABT-267
Simeprevir¹		BMS-791325
ABT-450 (with ritonavir)		Tegobuvir
Faldaprevir		GS-9669
Asunaprevir
GS-9451

¹Drugs have received Food and Drug Administration approval. Adapted from http://www.hepatitis.va.gov. HCV: Hepatitis C virus.

Citation: Hilgenfeldt EG, Schlachterman A, Firpi RJ. Hepatitis C: Treatment of difficult to treat patients. World J Hepatol 2015; 7(15): 1953-1963
URL: https://www.wjgnet.com/1948-5182/full/v7/i15/1953.htm
DOI: https://dx.doi.org/10.4254/wjh.v7.i15.1953

Hilgenfeldt EG, Schlachterman A, Firpi RJ. Hepatitis C: Treatment of difficult to treat patients. World J Hepatol 2015; 7(15): 1953-1963 [PMID: 26244069 DOI: 10.4254/wjh.v7.i15.1953]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.